Cd the broadening of the testing protocols through addition of other specific studies to the prechronic phases (single, 14-day, and 90-or Under the NTP, the carcinogenesis bioassay procedure(s) has been and continues to be changed to meet the objective of a broadened toxicologic characterization of chemicals and, further, to lead or stay abreast of advancing scientific developments. Prior to NTP involvement, the prechronic phases of the bioassay-which include single dose (acute), 14-day repeated dose, and 90-to 120-day repeated dose studies-were conducted to determine gross toxicity and general target organ effects at different dose levels as a primary basis for setting appropriate doses for the two-year bioassay studies. Now, the NTP has begun to gather routinely other information related to target organ effect: chemical disposition, fertility and reproduction, urinalysis, and hematology also are obtained from the prechronic studies-especially the 90-day study; certain other specific studies as applicable are included in the chronic two-year studies as well. Once those parameters that may be altered through exposure to the tested chemicals are identified, then suspect chemicals are referred to specific organ system groups for more detailed study of Thus, while the lifetime animal bioassay remains the best procedure for determining the carcinogenic potential of chemicals, NTP does not ordinarily use a standardized design. Rather the design is adapted to the special testing needs identified for the particular chemical. The NTP tailors its testing protocols to the particular chemicals based on the results from the prechronic testing phases, on available literature, and on structure-activity rela-195 tions. These new protocols permit better, more specific information to be generated for the tested compounds, which increases the effectiveness of the tests for potential human risk estimations. Such protocols also will be useful as guidelines for testing undertaken by other agencies and by industry. As examples, the NTP continues to pursue actively other design methodologies-increase the number of dose levels, "unbalanced" distribution of animals among dose groups, interim kills, and reduced essential histopathology.
Bioassay Results
During FY 1981, 23 long-term carcinogenesis bioassays were completed and the conclusions and data were evaluated and approved by the NTP staff review committee and subsequently by the external NTP peer review panel. Under the conditions of these carcinogenesis bioassays, 12 (52%) were considered negative, 10 (44%) positive, and 1 (4%) equivocal. One, polybrominated biphenyl (PBB) mixture (Firemaster FF-1), was conducted using a broadened experimental protocol aimed at providing a better dose-response determination (through use of six doses) and at giving more data on toxicologic end points other than induction of cancer. Nontumor toxicities of this PBB included porphyrogenic effects, decreases in serum thyroid hormones, hematotoxicity, enzyme alterations, and hepatotoxicity.
Since the NTP became actively involved in the carcinogenesis bioassay technical report review process, 40 experimental studies have been completed (with draft or final reports being issued): 20 (50%) positive, 14 (35%) negative, 4 (10%) equivocal, 2 (5%) inadequate; see Table 1 .
As of February 1982: (1) Twenty-five chemicals have been newly assigned to the testing laboratories (Table 2) . (2) Seventy-nine chemicals (89 separate studies) were in the prechronic testing 
